Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
Chronic Myeloid Leukemia
STAMP Inhibitor May Be a New Treatment Option in CML
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
